VDRM (ViaDerma) Debt-to-Equity: 0.21 (As of Jun. 2012)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is ViaDerma Debt-to-Equity?

ViaDerma VDRM -99.75% Debt-to-Equity is 0.21 as of Jun. 2012.

ViaDerma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2012 was $4.42 Mil. ViaDerma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2012 was $2.86 Mil. ViaDerma's Total Stockholders Equity for the quarter that ended in Jun. 2012 was $35.10 Mil. ViaDerma's debt to equity for the quarter that ended in Jun. 2012 was 0.21.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for ViaDerma's Debt-to-Equity or its related term are showing as below:

VDRM's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.28
* Ranked among companies with meaningful Debt-to-Equity only.

ViaDerma  (OTCPK:VDRM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

ViaDerma Debt-to-Equity Related Terms

ViaDerma Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for ViaDerma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ViaDerma Debt-to-Equity Chart

ViaDerma Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11
Debt-to-Equity
0.00 0.16 0.14 0.17 0.23

ViaDerma Quarterly Data
Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.26 0.23 0.22 0.21

VDRM vs AOLS, RDGL, PCYN: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ViaDerma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ViaDerma Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ViaDerma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where ViaDerma's Debt-to-Equity falls into.


ViaDerma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

ViaDerma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2011 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(4.356 + 3.32) / 33.56
=0.23

ViaDerma's Debt to Equity Ratio for the quarter that ended in Jun. 2012 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(4.42 + 2.862) / 35.098
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.21 mean?
ViaDerma (VDRM) has a Debt-to-Equity of 0.21 as of Jun. 2012. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on ViaDerma and its competitors.
Is ViaDerma's Debt-to-Equity too high?
ViaDerma's current Debt-to-Equity is 0.21. The Drug Manufacturers industry median Debt-to-Equity is 0.28. ViaDerma's value of 0.21 is 25% below this industry median.
How does ViaDerma's Debt-to-Equity compare to AOLS and RDGL?
ViaDerma's Debt-to-Equity of 0.21 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-Equity is 0.28. ViaDerma's value of 0.21 is 25% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ViaDerma's current Debt-to-Equity of 0.21 is 25% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on ViaDerma and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ViaDerma's current Debt-to-Equity is 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViaDerma stock overvalued right now?
ViaDerma (VDRM) has a current Debt-to-Equity of 0.21. The current Debt-to-Equity is 0.21 and 25% below the Drug Manufacturers industry median of 0.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For ViaDerma (VDRM), the current Debt-to-Equity is 0.21 as of Jun. 2012. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ViaDerma Business Description

Address 4640 Admiralty Way, Suite 500, Marina Del Rey, CA, USA, 90292
ViaDerma Inc is a specialty pharmaceutical company focused to bring new products to market through research and development. It is engaged in the business of manufacturing and sales of pharmaceuticals, and specifically topical antibiotics and pain management in the United States of America. Its sells under the brand name Vitastem. The Company also has products in development in the fields; anti-aging skin care, pain management, hair-loss, and toenail fungus.